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The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that 
dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients 
and by one-fifth in other patients, receiving oxygen therapy [1]. This equates to the prevention of 
one death in around eight ventilated patients, or one in around 25 patients requiring oxygen. This 
welcome news has been considered such an important therapeutic advance that the regimen has 
been fast-tracked in the UK even though the study has yet to attain peer review publication.
Although described by the investigators as ‘low dose dexamethasone therapy’ the dose is in effect 
five- to six6 fold greater than the therapeutic glucocorticoid replacement dose. High doses of 
glucocorticoids exacerbate hyperglycaemia in people with diabetes, may unmask undiagnosed 
diabetes and, in those at risk of diabetes, may precipitate hyperglycaemia and new-onset diabetes 
(commonly termed ‘steroid-induced diabetes’). Furthermore, glucocorticoids are the commonest 
cause of people with diabetes developing potentially life-threating hyperglycaemic hyperosmolar 
state (HHS) in hospital. To prevent these harms, the Joint British Diabetes Societies (JBDS) 
published guidelines on the management of inpatients with and without diabetes receiving steroid 
therapy [2]. However, these guidelines, which have been adopted in most UK hospitals, may not 
be appropriate for those with severe COVID-19 infection receiving dexamethasone, given the 
additional impact of the disease on glucose metabolism. The ‘cytokine storm’ resulting from 
severe COVID-19 infection is associated with significant insulin resistance and reduced insulin 
production from the pancreatic  cells. This dual pathology can precipitate severe hyperglycaemia, 
life-threatening ketoacidosis and HHS in people with diabetes, and even in people without, 
diabetes [3]. To prevent these harms, the UK National Diabetes COVID-19 response group 
published in this journal guidance on the management of COVID-19-related hyperglycaemia [4]. 
However, given the ‘triple insult’ of dexamethasone-induced impaired glucose metabolism, 
COVID-19-induced insulin resistance and COVID-19 impaired insulin production, we now 
provide new guidance specifically for use in people with severe COVID-19 infection commencing 
dexamethasone. The aim is to ensure that all patients commenced on dexamethasone, whether or 
not they have diabetes, receive appropriate glucose surveillance and management of 
hyperglycaemia should it occur. The guidance informs the clinician of the key facts pertaining to 
this clinical situation and the reasons why these recommendations differ from the JBDS 
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undertaken in those with and without diabetes and gives the target ranges of capillary blood 
glucose levels to aim for.
The guidance recommends giving correction doses of rapid-acting analogue insulin when capillary 
blood glucose > 12.0 mmol/l, with the dose calculated according to the patient’s weight or in those 
already treated with insulin, on their total daily insulin dose. The correction doses recommended 
are notably higher than those used in our previous hyperglycaemia guideline given the inevitable 
increase in insulin resistance. Unlike the previous guidance, we do not recommend using the 
insulin correction ratios that some people with type 1 diabetes usually use as these may not be 
appropriate given the significant disturbance of glucose metabolism.
To maintain glycaemic control we recommend using NPH insulin which has an intermediate 
duration of action in preference to longer-acting insulin even though the metabolic effects of 
dexamethasone can persist for up to 36 h. NPH insulin given twice daily allows more flexibility in 
dose adjustment. The starting doses based on weight are slightly greater than those given in our 
previous guidance but as before, a reduced dose should be used in the frail, elderly and those with 
an eGFR of < 30 ml/min. If the patient is already on a long-acting insulin or twice daily pre-mix 
insulin then it is recommended this be increased by 20%, but it is noted that this may actually 
require rapid escalation by 40% or more [5]. Insulin resistance will fall when dexamethasone is 
stopped and so capillary blood glucose and insulin dose adjustment need careful monitoring to 
avoid hypoglycaemia. The guidance table for the NPH and long-acting insulin assists in dose 
escalation and down titration of these insulins.
Finally, close initial follow-up is advised for those with known diabetes and a yearly HbA1c 
measurement is recommended for those with steroid-induced hyperglycaemia because this group 
have been shown to be at increased risk of developing diabetes at a later date.
We hope that these guidelines will be helpful for those managing patients with COVID-19 treated 
with dexamethasone in the ward setting. Although not intended for critical care units where 
policies around blood glucose monitoring may differ and where insulin is likely to be given by 
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COncise adVice on Inpatient  
Diabetes (COVID:Diabetes): 
DEXAMETHASONE THERAPY IN COVID-19 
PATIENTS: IMPLICATIONS AND GUIDANCE FOR 
THE MANAGEMENT OF BLOOD GLUCOSE IN 
PEOPLE WITH AND WITHOUT DIABETES 
NATIONAL INPATIENT DIABETES COVID-19 RESPONSE GROUP*
 o Key Facts
 › Dexamethasone reduces mortality in people with COVID-19 who require ventilation or oxygen therapy
 › Corticosteroid therapy impairs glucose metabolism and is the commonest cause of life threatening inpatient Hyperglycaemic Hyperosmolar Syndrome (HHS)
 › COVID-19 increases insulin resistance and impairs insulin production from the pancreatic beta cells; this can precipitate hyperglycaemia and life 
threating Diabetic Ketoacidosis (DKA) in people with diabetes and even in people not known to have diabetes 
 › Glucose levels above 10.0 mmol/L have been linked to increased mortality in people with COVID-19
 › The recommended dexamethasone dose of 6mg/day (oral or IV) for 10 days, equivalent to 40mg of prednisolone/day, will undoubtedly afect  
glucose metabolism 
 › Thus, the triple whammy of dexamethasone induced impaired glucose metabolism, COVID-19 induced insulin resistance and COVID-19 related impaired 
insulin production could result in signiicant hyperglycaemia, HHS and DKA in people with and without diabetes, increasing both morbidity and mortality
 › Sulphonylureas are NOT recommended in this context as beta cell function may be impaired and insulin resistance is likely to be severe.  For this reason, 
these recommendations difer from those in the JBDS guideline on the Management of Hyperglycaemia and Steroid (Glucocorticoid) Therapy
AIMS
 q To ensure ALL patients on dexamethasone receive appropriate  glucose surveillance and appropriate management of hyperglycaemia 
GLUCOSE MONITORING
Target glucose 6.0 -10.0 mmol/L (up to 12.0 mmol/L is acceptable) 
Frequency of monitoring
 › People not known to have diabetes 
Check the glucose at least 6 hourly ideally at fasting periods (e.g. before meals and at bedtime). If after 48 hours all fasting glucose results are <10.0 mmol/L reduce 
frequency to once daily at 17.00-18.00 hrs.  Continue until dexamethasone is stopped 
If any fasting glucose is above 10.0 mmol/L continue 6 hourly monitoring and follow the guidance below to correct hyperglycaemia i.e. glucose above 12.0 mmol/L
 › People with diabetes 
Throughout the admission, check fasting glucose at least 6 hourly, or more frequently if the glucose is outside the 6.0 -10.0 mmol/L range
 q This guidance is for use in ALL patients with COVID-19 who are treated with dexamethasone in a ward setting
It is NOT intended for Critical Care Units but may be adapted for this use  
It difers from the previous COVID: Diabetes GUIDANCE FOR MANAGING INPATIENT HYPERGLYCAEMIA as it targets the greater 















MANAGING DEXAMETHASONE RELATED HYPERGLYCAEMIA
First, exclude Diabetic Ketoacidosis and Hyperglycaemia Hyperosmolar Syndrome by checking blood glucose, ketones, venous pH, bicarbonate and U&Es and if DKA/HHS 
diagnosed follow speciic guidelines for their management 
  If DKA/HHS have been excluded, follow the guidance below but note, this advice is conservative. If after initial treatment hyperglycaemia persists, do not 
hesitate to escalate to the next treatment step and involve the diabetes team as early as possible 
ADVICE FOR CORRECTING INITIAL HYPERGLYCAEMIA - GLUCOSE ABOVE 12.0 MMOL/L
Use subcutaneous rapid acting insulin analogue (Novorapid®/Humalog®/Apridra®) as described below. Note these are conservative doses and depending on response in 
individual patients, as previously stated, may need to be increased rapidly (or where more insulin sensitive, decreased) 
Recheck glucose at 4 hrs to determine response and whether a further correction dose is needed
 › Insulin naïve
Follow the weight-based tables below in those people: 
 » not known to have diabetes 
 » with type 2 diabetes treated with diet alone or with oral hypoglycaemic agents
 › Insulin treated 
Where the total daily dose (TDD) of insulin is known follow the guidance in the table based on TDD. If the TDD is unknown, follow guidance according to the person’s weight 
CORRECTION DOSES OF RAPID ACTING INSULIN 
GLUCOSE
(MMOL/L)
• TDD = <50 UNITS  
PER DAY
• 0R WEIGHT < 50 KG
• TDD = 50 -100 UNITS 
PER DAY
• 0R WEIGHT 50 -100 KG
• TDD = >100 UNITS  
PER DAY
• 0R WEIGHT  >100 KG 
12.0-14.9 2 units 2 units 4 units • Please check KETONES if 
glucose >12.0mmol/L
  If KETONE >1.5mmol/L, 
for doctor review
  If KETONE >3.0mmol/L 
Exclude DKA-Venous pH, 
bicarbonate, lab glucose, 
U&E. Refer to diabetes team
15.0-16.9 2 units 3 units 5 units
17.0-18.9 3 units 4 units 5 units
19.0-20.9 3 units 5 units 6 units
21.0-22.9 4 units 6 units 7 units
23.0-24.9 4 units 7 units 8 units
25.0-27.0 5 units 8 units 9 units
Over 27 6 units 9 units 10 units
MAINTAINING GLYCAEMIC CONTROL 
 › People NOT on an intermediate acting (NPH) or long acting insulin: 
Where glucose has risen above 12.0 mmol/l due to dexamethasone treatment, start NPH insulin which has an intermediate duration of action (e.g. Humulin I®, Insulatard®) 
- total dose 0.3 units/kg/day. Give 2/3 of the total daily dose in the morning (07.00 – 08.00) and the remaining 1/3 in the early evening (17.00-18.00). e.g. 0.3 x 80kg = 24 
units/d i.e. 16 units a.m. and 8 units p.m. ). NOTE- there should be a low threshold for dose escalation (see table below) and referral to the diabetes team 
NPH insulin twice daily is recommended as this gives more lexibility with dose adjustment. However, the metabolic efects of dexamethasone can persist for up to 36 
hours, thus a longer acting basal analogue insulin may also be considered. See tables below for dose adjustment of long acting insulin and twice daily intermediate 
and long acting insulins
  ALERT NOTE - if:
 › Older (>70 yrs) or frail
 › Serum creatinine >175 umol/l (eGFR <30 ml/min)
Use a reduced NPH insulin dose of 0.15 units/kg (e.g. 0.15 x 80kg = 12 units i.e. 8 units a.m. and 4 units p.m.) NOTE- there should be a low threshold for dose 
escalation and referral to the diabetes team
 › People already using once or twice daily long-acting insulin or twice daily NPH including those on basal-bolus regimens 
Increase the long acting basal or NPH insulin by 20% but this may need rapid escalation by as much as 40% depending on response. Titrate the dose using the tables 
below.  Patients on basal-bolus regimens may not require ‘mealtime’ insulin boluses if not eating, however, if hyperglycaemia persists during adjustment of basal insulin 
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 › People on twice-daily pre-mix insulin 
e.g. NovoMix 30®/Humulin M3®/Humalog Mix 25®/Humalog Mix 50®
Continue mixed insulin and adjust dose (follow dose adjustment for long-acting insulin table below). Consider increasing the morning dose by 20% but this may need 
rapid escalation by as much as 40% each day depending on the response.  There should be a low threshold for referral to the diabetes team 
DOSE ADJUSTMENT FOR LONG-ACTING INSULIN
Doses can be titrated daily, although longer-acting insulins may take 48-72 hours to reach steady state. Dose adjustments will afect blood glucose throughout the day
ONCE daily long-acting insulin TWICE daily NPH or long-acting insulin
GLUCOSE LEVEL JUST 
BEFORE INSULIN DOSE
GLUCOSE LEVEL JUST BEFORE MORNING  
INSULIN DOSE
JUST BEFORE EVENING  
INSULIN DOSE
<4mmol/L Reduce insulin by 20% <4mmol/L Reduce evening insulin  by 20% Reduce morning insulin by 20%
4.1-6mmol/L Reduce insulin by 10% 4.1-6mmol/L Reduce evening insulin by 10% Reduce morning insulin by 10%
6.1-12mmol/L No change 6.1-12mmol/L No change No change
12.1-18mmol/L Increase insulin by 10% 12.1-18mmol/L Increase evening insulin 10% Increase morning insulin by 10%
>18mmol/L Increase insulin by 20% >18mmol/L Increase evening insulin by 20% Increase morning insulin by 20%
 › People using a personal insulin infusion pump
If the person is too unwell to manage their pump, transfer to a Variable Rate Intravenous Insulin Infusion (VRIII) with a basal insulin given alongside - seek the advice 
of the diabetes team.  If the pump is removed, give the pump to a relative for safekeeping or label with the patients details and safely store 
Those people well enough to manage their subcutaneous insulin infusion pump should be recommended to initially increase the basal rates by 20% and be made 
aware that this may need to be increased further on a daily basis. Refer all people using a personal insulin pump to the diabetes team
END OF DEXAMETHASONE THERAPY- DAY 10 
Insulin resistance will begin to fall when the dexamethasone has been stopped but may take a number of  days. Continue to monitor glucose 6 hourly and down titrate 
using the guidance table above 
DISCHARGE AND FOLLOW-UP
 › Diabetes precipitated by COVID-19 infection and dexamethasone treatment
Normoglycaemia may be established after stopping dexamethasone without the need for ongoing diabetes therapy. However, up to a third of people may later develop 
diabetes therefore alert the GP that the patient will need a yearly HbA1c measurement
 › People with known diabetes 
These patients will require close support following discharge. The discharge guidelines and patient information lealet produced by this group are available to 
facilitate this. The lealet can be accessed here: https://www.diabetes.org.uk/professionals/resources/shared-practice/inpatient-and-hospital-care#patients
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
